首页> 外文期刊>Orthopaedic Journal of Sports Medicine >The transosseous ACL Refixation and biological Augmentation 'TARBA'. Preliminary Results of a new Operation Technique
【24h】

The transosseous ACL Refixation and biological Augmentation 'TARBA'. Preliminary Results of a new Operation Technique

机译:骨间ACL固定和生物增强“ TARBA”。一种新的操作技术的初步结果

获取原文
获取外文期刊封面目录资料

摘要

Aims and Objectives: Differentiated gradings of anterior cruciate ligament (ACL) tear-types allow us to perform a more and more differentiated treatment of this injury. Especially in the tears close to the insertion ACL preserving techniques like "healing response" together with growth factors or synthetic augmentations of the original ACL like the "dynamic intraligamentous stabilization DIS" have increasing importance. Disadvantages of the mentioned techniques are the limited indications and the high need of material. That led us to the development of the "transosseous ACL refixation and biological augmentation TARBA", in which the original ACL is refixed to the femoral insertion and augmented with the patient’s doubled gracilis tendon. In the following we will present the first results with this technique. Materials and Methods: From 12/2013 to 02/2015 we used this technique in 56 patients (28x m, 28x f, age 30.7years). All patients had ACL tears in the proximal third close to the femoral insertion. The original ACL was fixed arthroscopically with 2 PDS fibres. Those were pulled out of the femur through a 5mm channel. The original-ACL was augmented with a doubled ipsilateral gracilis tendon. This tendon graft was pulled into the joint via another tibial 5mm channel and fixed at the femur with an endobutton and at the tibia with a cortical anchor screw. Both channels were placed exactly adjacent to the centre of the femoral and tibial anatomic insertion sites. The treatment result was controlled after 3, 6, 9 and 12 months with clinical examination and various scores (patient satisfaction, VAS, Lysholm, Tegner, Activity Rating Scale). After 6 months an instrumented stability test (Rolimeter) was performed. All patients were matched with 47 patients who had a complete ACL tear treated with 4-strand stemitendinosus tendon (control group). Results: Until now all patients with "TARBA" were satisfied with their operation. The range of motion was equal to the healthy side. Anterior-posterior stability in the Lachman test was equal to the healthy side. Rolimeter-test after 6 months showed an average side difference of less than 1mm. The Pivot-Shift test was 1x positiv in 3 patients. WE had to do 3 revisions (1x traumatic Re-tear, 1x traumatic meniscal tear, 1x limited range of extension). Compared with the control group with complete ACL replacements there was no sicnificant difference in the various scores. Conclusion: With "TARBA" the original ACL can be preserved. For augmentation only a rather thin tendon in small channels is "wasted". This new technique shows excellent subjective and objective results within the follow-up period we overlook. If we can prove these findings during the follow-up to come this technique to preserve the native ACL will enlarge the range of treatment options in ACL surgery significantly.
机译:目的和目的:前交叉韧带(ACL)撕裂类型的差异化等级使我们能够对该损伤进行越来越多的差异化治疗。尤其是在泪水接近插入的ACL保留技术(如“愈合反应”),生长因子或原始ACL的合成增强(如“动态韧带稳定DIS”)的合成中,其重要性日益提高。所提到的技术的缺点是适应症有限并且对材料的高度需求。这导致我们开发了“经骨ACL固定和生物增强TARBA”,其中原始ACL被固定在股骨插入处,并通过患者的双重gra肌腱进行增强。在下面,我们将介绍该技术的第一个结果。材料和方法:从12/2013到02/2015,我们对56例患者(28x m,28x f,年龄30.7岁)使用了该技术。所有患者在靠近股骨插入处的近端三分之一处都有ACL撕裂。最初的ACL用2根PDS纤维在关节镜下固定。那些通过5mm通道从股骨中拉出。原来的ACL增加了同侧psi肌腱的两倍。将该肌腱移植物通过另一个5mm胫骨通道拉入关节,并用内扣固定在股骨上,并用皮质锚固螺钉固定在胫骨上。这两个通道都完全位于股骨和胫骨解剖插入部位的中心。在3、6、9和12个月后通过临床检查和各种评分(患者满意度,VAS,Lysholm,Tegner,活动评定量表)控制治疗结果。 6个月后,进行了仪器稳定性测试(Rolimeter)。所有患者均与47例接受了4线迷路肌腱的完全ACL撕裂患者匹配(对照组)。结果:到目前为止,所有“ TARBA”患者对手术均满意。运动范围等于健康方面。 Lachman测试中的前后稳定性与健康方面相同。 6个月后的眼振仪测试显示平均侧差小于1mm。 3例患者的Pivot-Shift检验为1x阳性。我们必须做3次修订(1次外伤性撕裂,1次外伤性半月​​板撕裂,1次延伸范围有限)。与完全替代ACL的对照组相比,各个评分没有显着差异。结论:使用“ TARBA”可以保留原始ACL。为了增强,仅“浪费”了小通道中相当细的肌腱。在我们忽略的后续期内,这项新技术显示了出色的主观和客观结果。如果我们能够在后续随访中证明这些发现,那么该技术可以保护天然ACL,从而大大扩大ACL手术的治疗范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号